TABLE 3 from A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
Best response by RECIST in evaluable patients treated at RP2D (pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily).
创建时间：
2023-06-08
